Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | ALPI | P09923 | 1/20 | 0.41 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.41 |
| ▸ | XIAP | P98170 | 1/20 | 0.41 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.39 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.39 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.39 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL4223168 | 0.98 | SLC7A5 (0.46) | CYP1A2SLC7A5CYP3A4HSD17B10PKM | |
| Histidine SCHEMBL10879497 | 0.97 | CYP1A2 (0.47) | CYP1A2SLC7A5CYP3A4HSD17B10PKM | |
| Histidine SCHEMBL3258 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4HSD17B10PKM | |
| Histidine SCHEMBL163443 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4HSD17B10PKM | |
| Histidine SCHEMBL3259 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4HSD17B10PKM | |
| Histidine SCHEMBL18824897 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4HSD17B10PKM | |
| Histidine SCHEMBL388563 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4HSD17B10PKM | |
| Histidine SCHEMBL163442 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4HSD17B10PKM | |
| Histidine SCHEMBL995910 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4HSD17B10PKM | |
| Histidine SCHEMBL8080341 | 0.97 | SLC7A5 (0.47) | CYP1A2SLC7A5CYP3A4HSD17B10PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4704914-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATES COMPRISING PNU-159682 DERIVATIVES | Merck Sharp & Dohme LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4701667-A1 | TROP2 BINDERS AND CONJUGATES THEREOF | Merck Sharp & Dohme LLC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20240358847-A1 | TROP2 BINDERS AND CONJUGATES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2024226388-A1 | ANTI-TROP2 ANTIBODY-DRUG CONJUGATES COMPRISING PNU-159682 DERIVATIVES | MERCK SHARP & DOHME LLC (US) | 2024-10-31 | — | — | WO | disclosed |
| WO-2024226410-A1 | TROP2 BINDERS AND CONJUGATES THEREOF | MERCK SHARP & DOHME LLC (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20090081121-A1 | LIPOSOME COMPOSITIONS USEFUL FOR TUMOR IMAGING AND TREATMENT | NATIONAL HEALTH RESEARCH INSTITUTE (TW) | 2009-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240358847-A1 | TROP2 BINDERS AND CONJUGATES THEREOF | TPM3, TPM4, CD2BP2 | CYP1A2 2322/4885SLC7A5 2990/4885CYP3A4 3600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.